Daily Alpha · Reddit
· Premarket Alpha · by Buzzberg Research
Retail flows are concentrated in AMD and Palantir earnings debates, while single-name ideas span optics, biotech, preferreds and political hedges.
Themes on this desk
AMD earnings positioning
Retail posters are adding AMD at $466-$475 into earnings, with one targeting above $550; a bear warns high valuation and macro risk could push it toward $400.
Palantir post-earnings debate
Palantir's 96% revenue growth and commercial mix shift have not settled the valuation debate; holders see sticky demand, while near-term weakness is blamed on AI sentiment.
Reddit user-growth controversy
A long RDDT holder says the DAU decline is low-monetizing logged-out search traffic; a value investor calls the user trend a long-term decline and value trap.
Highest engagement
by score · day changeIntel bears say the selloff is deserved on products, fabs and partnerships
A poster argues Intel's punishment is fair given supply-chain, demand-reading, product-competitiveness and partnership failures, and that Intel ex-fabs is not turning around.
But punishing Intel is fair given that: 1.
The debate shifts from valuation to execution: without product wins and fab credibility, a low multiple is not a catalyst.
Watch Intel's product competitiveness, demand reading and partnership progress.
Source →AAOI holder says optics demand and in-house lasers make the selloff unjustified
A shareholder argues AAOI is unfairly depressed by deleveraging and shorting despite strong optics demand, in-house lasers and a 1H 2027 inflection, and expects an earnings beat.
AAOI valuation What pisses me of is the valuation of AAOI and how it has nothing to do with the
If the thesis is right, the market is pricing balance-sheet stress over operating demand; the earnings print is a near-term test.
Watch AAOI's next earnings, laser capacity ramp and 1H 2027 inflection.
Source →INO bull case leans on FDA approval, 25% short interest and hard-to-borrow setup
A biotech poster flags INO as bullish after an FDA approval, with 25% short interest, hard-to-borrow conditions and catalysts.
INO. ( FDA Approved) plus 25% SI and hard to borrow and bullish news and catalyst.
The setup is a squeeze-style biotech trade; FDA approval is the fundamental anchor, but borrow stress can amplify moves.
Watch Short interest, borrow fees and FDA approval commercialization.
Source →Boston Scientific valuation work points to $40 entry with about $34 downside
Using management's flat-growth guidance and normalized EPS, the poster values Boston Scientific as a buy near $40 with limited downside to about $34.
Boston Scientific (Bsx). Some comments. Boston Scientific (Bsx) a simple valuation Just a comment on valuation:
The note frames BSX as a turnaround bet where the entry price, not the current price, determines risk/reward.
Watch BSX growth guidance, normalized EPS and whether shares reach the $40 entry.
Source →Reliance sum-of-parts leaves New Energy battery optionality unvalued
A holder bought more Reliance Industries, arguing Jio, O2C and Retail sum-of-parts leave the New Energy battery business unvalued, while flagging reduced disclosure and timeline ambiguity on the 40GWh plant.
Anyone following Reliance closely? What is happening with New Energy Business Especially after Jio IPO, i felt Reliance Industries is
The post frames Reliance as a sum-of-parts story with an unvalued New Energy battery business and flags reduced disclosure and timeline ambiguity on the 40GWh plant.
Watch Reliance's New Energy 40GWh plant timeline and segment disclosure.
Source →Most argued
by comments per upvoteAlphabet's GOOGN preferred yields about 7.57%, but buyer waits
A dividend investor is watching Alphabet's GOOGN preferred shares yielding about 7.57% at $41.25, with the main risk being further price decline; they have not bought yet.
Preferred Google Shares Earlier this summer Google issued preferred shares that trade under symbol GOOGN.
The preferred offers a high current yield on Alphabet's cash flow, but price risk can overwhelm carry if rates or spreads widen.
Watch GOOGN price and whether the 7.57% yield compensates for further decline.
Source →Spotify's international pricing faces free-YouTube substitution
A commenter argues free YouTube with ad-block in ex-US markets undercuts Spotify's ability to charge for family plans abroad.
People put on hour long Latin mix or pop mix on YouTube (not YouTube music) with ad block for free
The argument is a direct challenge to Spotify's international family-plan pricing lever; if valid, it limits pricing power outside the US.
Watch Ex-US subscriber net adds, family-plan pricing and churn.
Source →Apple put buyer says AI payments to Alphabet may exceed $1B a year
A poster bought Apple puts, arguing Apple may be paying Alphabet far more than the rumored $1B a year for AI, citing Alphabet's deferred-revenue jump and Apple's cited Siri AI cost pressure on gross margin.
Is Apple far more paying for Alphabet's AI than the rumored USD 1b per year? I think so.
If AI inference costs are larger and stickier than the rumored $1B figure, Apple's services gross margin could face pressure; the poster expresses this through put options.
Watch Alphabet deferred revenue, Apple's services gross margin and any AI contract disclosure.
Source →TSLA put idea hinges on Democratic midterm wins
An options poster considers buying TSLA puts on the thesis that Democratic midterm wins could push the stock down given Elon Musk's Republican support.
TSLA puts TSLA has been running well lately, although I think that the midterm results can bring it down.
The trade is a political-risk expression, not an operating view; it highlights how Musk's politics can add idiosyncratic volatility.
Watch Midterm results and any post-election policy response affecting Tesla.
Source →